(Reuters) - The drop comes just over a month after the stock more than doubled in a single session when a U.S. Food and Drug Administration advisory panel recommended approval of the vaccine, Provenge.
Read more at Reuters.com Hot Stocks News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment